OR WAIT null SECS
October 19, 2022
Gilead and MacroGenics will work together on bispecific antibodies for the treatment of blood cancers.
Ebvallo (tabelecleucel) would be the first EMA-approved therapy for patients with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease.
Takeda’s dengue vaccine is designed to prevent disease caused by virus serotypes 1, 2, 3, and 4 in individuals four and older.
October 14, 2022
Merck has exercised a $250 million option with Moderna to jointly develop and commercialize cancer vaccine mRNA-4157/V940.
Alexion’s acquisition of LogicBio is designed to accelerate the company’s growth in genomic medicines.
October 13, 2022
FDA amended its authorization for the Moderna and Pfizer-BioNTech bivalent booster vaccines to permit their use in children as young as five years old.
Russell Kneipp, who has been Spectrum’s COO since 2018, will assume the roles effective immediately.
October 12, 2022
CRB’s Horizons: Life Sciences report covers challenges facing manufacturers and how to keep pace with rapid innovation.
Eli Lilly and Company will partner with Schrödinger to develop and optimize small molecule compounds.
CBER maps modernization plan to handle surge in research and applications.